Xtant Medical

News

Xtant Medical Reports Second Quarter 2017 Financial Results

Company Continues to Take Steps During Restructuring to Build for Future Growth BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the quarter ended June 30th, 2017. The Company reported Second Quarter 2017 revenue of approximately $21.4 million and an EBITDA loss of approximately ($2.1) million for the period. Reven…
Read more

Xtant Medical Receives FDA Clearance for Calix-C Cervical Interbody Line Extension and Expanded Indications

BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Calix-C family of cervical interbody cages.  The clearance provides for the addition of two larger footprints and importantly, for use with allograft.  This clearance strengthens Xtant Medical’s focu…
Read more

Xtant Medical Joins the 2018 Donate Life Rose Parade Float to Highlight the Power of Organ, Eye, and Tissue Donation

BELGRADE, Mont., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, is proud to announce its sponsorship of the 2018 Donate Life float at the January 1 Rose Parade® in Pasadena. The Donate Life float, now in its 15th year, is part of a national effort of more than 50 organizations that have teamed up to deliver the simple, life giving message that the kind and generous act…
Read more

Xtant Medical to Announce Second Quarter 2017 Results on August 9th, 2017

BELGRADE, Mont., July 24, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 9, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chief Financial …
Read more

Xtant Medical Announces Rescheduling of Annual Meeting

BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the Company's annual meeting of stockholders, originally scheduled for June 21, 2017, to a later date, as the Company continues to evaluate its strategic alternatives. The Company will announce a new annual meeting date and record date when they are deter…
Read more

Xtant Medical Enters into Licensing Agreement for Sites Medical’s OsteoSync Ti Technology

BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC, for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. "We are very excited to work with Sites Medical," said Carl O'Connell, CEO of Xtant Medical.…
Read more

Xtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners

BELGRADE, Mont., May 12, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into an amendment to its senior credit facility with affiliates of OrbiMed Advisors (“OrbiMed”) for a financing of up to $15 million with the proceeds being used to pay off its outstanding balance of approximately $9 million under its accounts receivable credit facility with Sili…
Read more

Xtant™ Medical Reports First Quarter Revenue of $22.1 million, 5% Growth Compared to the Prior Year Period

First Quarter 2017 Highlights: Consolidated total revenue increased 5.3% to $22.1 million compared to first quarter 2016 revenue of $21.0 million Consolidated gross profit increased 10.1% to $15.5 million compared to first quarter 2016 gross profit of $14.1 million Consolidated gross margins improved to 70.3%, compared to 67.2% reported in the first quarter of 2016 The Company reported an EBITDA gain of approximately $577,000 for the first quarter of 2017 BELGRADE, Mont., May 09, 2017 (GLOBE …
Read more

Xtant Medical Announces Release of First Quarter 2017 Results on May 9, 2017

BELGRADE, Mont., May 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it will release its financial results for the First Quarter ended March 31st, 2017, at the close of the financial markets on Tuesday, May 9th. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chief Financial Officer, to revie…
Read more

Xtant Medical Recognized as Montana Ambassador Business of the Year

BELGRADE, Mont., April 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has been named as the Montana Ambassador Business of the Year. Xtant Medical was honored for making an outstanding contribution to the economic development in Montana.

"We are incredibly humbled to receive this recognition …

Read more

Xtant™ Medical Receives Going Concern Opinion

BELGRADE, Mont., April 05, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016, which was filed on March 29, 2017 with the Securities and Exchange Commission, its audited financial statements contained a going concern qualification paragraph in the audit opinion from its inde…
Read more

Xtant™ Medical Reports Record Fourth Quarter Revenue of $24.5 million, 10% Growth Compared to Prior Year Period

See footnote about the use of pro forma financial information Fourth Quarter 2016 Highlights: Consolidated total revenue increased 9.9% to a record $24.5 million compared to fourth quarter 2015 revenue of $22.3 million Consolidated gross profit increased 17.4% to $17.5 million compared to fourth quarter 2015 gross profit of $14.9 million Consolidated gross margins improved to 71.6%, compared to 67.0% reported in the fourth quarter of 2015 Full-Year 2016 Highlights: Consolidated gross profit i…
Read more